Forest Excels: Celexa, Lexapro Help Company In Down Quarter On Wall Street
Executive Summary
Forest Labs is off to a fast start in fourth quarter trading, as the company has found a winning formula during a prolonged down market for brand name pharmaceutical stocks
You may also be interested in...
Schering under SEC investigation
Schering-Plough's handling of an earnings warning issued Oct. 3 has prompted an inquiry by the Securities & Exchange Commission. The company lowered its outlook for the third quarter and warned of an earnings decline in 2003; the company's stock dropped 15% in the two days leading up to the formal announcement (1"The Pink Sheet" Oct. 7, p. 19)...
Schering under SEC investigation
Schering-Plough's handling of an earnings warning issued Oct. 3 has prompted an inquiry by the Securities & Exchange Commission. The company lowered its outlook for the third quarter and warned of an earnings decline in 2003; the company's stock dropped 15% in the two days leading up to the formal announcement (1"The Pink Sheet" Oct. 7, p. 19)...
Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half
Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results